SCHEMBL6967029

SCHEMBL6967029

COc1ccc2cc(C=O)c(=O)oc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.58
HPGD P15428 5/20 0.58
MAOB P27338 5/20 0.58
GAA P10253 4/20 0.58
GLA P06280 4/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
SLC16A3 O15427 1/20 0.58
CA12 O43570 3/20 0.57
CA9 Q16790 3/20 0.57
CA1 P00915 2/20 0.57
CA2 P00918 2/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
KDM4E B2RXH2 6/20 0.57
HSD17B10 Q99714 2/20 0.57
CA3 P07451 2/20 0.57
CA4 P22748 2/20 0.57
CA6 P23280 2/20 0.57
CA7 P43166 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7033540 0.88 KDM4E (0.58) ALDH1A1HPGDMAOBGAACA12
SCHEMBL13620670 0.82 KDM4E (0.62) ALDH1A1HPGDMAOBGAAGLA
SCHEMBL29002816 0.81 CA12 (0.62) ALDH1A1HPGDMAOBGAAGLA
SCHEMBL13486864 0.80 ALDH1A1 (0.61) ALDH1A1HPGDMAOBGAAGLA
SCHEMBL28533299 0.80 MAOB (0.57) ALDH1A1HPGDMAOBGAAGLA
SCHEMBL13486865 0.79 ALDH1A1 (0.53) ALDH1A1HPGDMAOBGAAGLA
SCHEMBL15842248 0.79 ALDH1A1 (0.63) ALDH1A1HPGDMAOBGAAGLA
SCHEMBL566297 0.79 APP (0.58) ALDH1A1HPGDMAOBGAAGLA
SCHEMBL5288407 0.79 ALDH1A1 (0.60) ALDH1A1HPGDMAOBGAAMEN1
SCHEMBL10305766 0.79 ALDH1A1 (0.63) ALDH1A1HPGDMAOBGAAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017114877-A1 FLUORESCENT PARTICULATE MATERIAL L'OREAL (FR) 2017-07-06 WO disclosed
US-20100048604-A1 Ligands for Aldoketoreductases TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2010-02-25 US disclosed
US-6545031-B1 Carboxyalkenylpyrazolylbenzene derivatives, such as (E)-alpha-((5-(2-((2-carboxyphenyl)methoxy)-4-methoxyphenyl) -1-ethyl-1H-pyrazol-4-yl)methylene)-6-methoxy-1,3-benzodioxole -5-propanoic acid SMITHKLINE BEECHAM CORPORATION 2003-04-08 US disclosed
EP-0841926-B1 ENDOTHELIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2003-03-26 EP disclosed
EP-0843551-B1 ENDOTHELIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-02-06 EP disclosed
US-6174906-B1 TREATMENT OF DISEASES CAUSED BY AN EXCESS OF ENDOTHELIN COMPRISING ADMINISTERING ENDOTHELIN RECEPTOR ANTAGONIST COMPOUND; FOR TREATING UNSTABLE ANGINA, CORONARY VASOSPASM AND MYOCARDIAL SALVAGE, RESTENOSIS, PULMONARY HYPERTENSION SMITHKLINE BEECHAM CORPORATION 2001-01-16 US disclosed
US-6030970-A TREATING RENAL FAILURE OR CEREBROVASCULAR DISEASE, RADIO-CONTRAST INDUCED RENAL FAILURE, CONGESTIVE HEART FAILURE, UNSTABLE ANGINA, CORONARY VASOPASM, MYOCARDIAL SALVAGE, RESTENOSIS, PULMONARY HYPERTENSION, STROKES SMITHKLINE BEECHAM CORPORATION (US) 2000-02-29 US disclosed
EP-0841926-A4 ENDOTHELIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 1999-08-04 EP disclosed
EP-0843551-A4 ENDOTHELIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 1998-08-12 EP disclosed
EP-0843551-A1 ENDOTHELIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1998-05-27 EP disclosed
EP-0841926-A1 ENDOTHELIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1998-05-20 EP disclosed
WO-1997004774-A1 ENDOTHELIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-02-13 WO disclosed
WO-1997004773-A1 ENDOTHELIN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-02-13 WO disclosed
US-4098799-A ANTIALLERGENS, HYPERACIDITY WARNER-LAMBERT COMPANY (US) 1978-07-04 US disclosed
US-4008252-A ANTIALLERGENS, ANTIHYPERACIDITY WARNER-LAMBERT COMPANY (US) 1977-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048604-A1 Ligands for Aldoketoreductases AKR1C2, AKR1C1, AKR1B1 ALDH1A1 18/4885HPGD 59/4885MAOB 557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.